Everest Organics announced yesterday that they are all set to manufacture Remdesivir API at their Hyderabad facility 

Dr Sirisha Srikakarlapudi, Director, EOL – New Product Development said, “lt’s a moment of utmost satisfaction that with hard work of the past few months by Everest Organics R&D team, we have been able to successfully develop remdesivir API at lab scale in a short span of time. In fact, we are poised for the development of more products in the anti-viral segments in the future.”

The company was incorporated on 19.02.1993 to carry on the business of manufacturing of bulk drugs viz. Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Benzimadizole, etc., having its factory at Sadasivpet Medak District Hyderabad. The construction activities have started in the year 1994 and the commercial production of the company has started in 1996. During the Year 1995 the company went into public issue and the shares of the company have been over-subscribed by 39.632 times. With full swing, the company started its production and got a good market share for their products.

The Company is headed by Dr. S.K. Srihari Raju who is an NRI and also a Doctor by profession. He brings in his rich and varied experience of more than 25 years in the field of Medical Science to develop Products and enhance marketablity by focusing on Therapeutic areas which are of strategic importance and growth.

Recently, Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, announced that its subsidiary, Jubilant Generics Limited (“Jubilant”), has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant’s 24-hour helpline will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

In order to increase the accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir (“JUBI-R”) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19. ‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

“It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has the potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and in other countries,” stated Mr. Shyam S. Bhartia, Chairman & Managing Director and Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited. “The Company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to providing leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on a compassionate basis to save precious lives of people through unique programs.”